Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Trametinib and Everolimus for the Treatment of Pediatric and Young Adult Patients with Recurrent Low Grade and High Grade Gliomas

Trial Status: active

This phase I trial studies the side effects and best dose of trametinib and everolimus in treating pediatric and young adult patients with low grade and high grade gliomas that have come back (recurrent). Trametinib acts by targeting a protein in cells called MEK and disrupting tumor growth. Everolimus is a drug that may block another pathway in tumor cells that can help tumors grow. Giving trametinib and everolimus may work better to treat low grade and high grade gliomas compared to trametinib or everolimus alone.